Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Медикаментозные средства в реабилитации больных после инфаркта миокарда: ингибиторы ангиотензинпревращающего фермента
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В работе проведен анализ применения ангиотензинпревращающего фермента (ИАПФ) у больных после перенесенного инфаркта миокарда (ИМ). Представлены данные контролируемых исследований, показывающих обоснованность применения ИАПФ для улучшения прогноза больных. Сделан вывод о том, что неназначение врачом ИАПФ больным после ИМ с явной или бессимптомной дисфункцией левого желудочка, а также больным сахарным диабетом (при отсутствии противопоказаний) является неоправданным.
Ключевые слова: ингибиторы ангиотензинпревращающего фермента, инфаркт миокарда, сердечная недостаточность.
Ключевые слова: ингибиторы ангиотензинпревращающего фермента, инфаркт миокарда, сердечная недостаточность.
________________________________________________
The paper analyzes the use of angiotensin-converting enzyme (ACE) inhibitors in patients after prior myocardial infarction. It presents the data of controlled studies, which indicate that it is warranted to use ACE inhibitors to improve prognosis in patients. It is concluded that it is unreasonable for a physician not to prescribe ACE inhibitors to post-myocardial infarction patients with obvious or asymptomatic left ventricular dysfunction and to diabetic patients (if no contraindications).
Key words: angiotensin-converting enzyme inhibitors, myocardial infarction, heart failure.
Полный текст
Список литературы
1. Dargie HJ, McAlpine M, Morton JJ. Neuroendocrine activation in acute myocardial infarction. J Cardiovasc Pharmacol 1987; 9 (Suppl. 2): S21–4.
2. Pfeffer JM, Pfeffer M, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57: 84–95.
3. Pfeffer MA, Braunwald EA, Moyé LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992; 327: 669–77.
4. De Kam PJ, Voors AA et al. Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilatation after myocardial infarction in patients receiving thrombolysis. J Am Coll Cardiol 2000; 36: 2047–53.
5. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. The prognostic value of predischarge quantitative two-dimensional echocardiographyc measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 trial. Eur Heart J 1996; 17: 1646–56.
6. Greenberg B, Quinones MA et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left netricular dysfunction. Results of the SOLVD Echocardiographic Study. Circulation 1995; 91: 2573–81.
7. Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy. Lancet 1993; 342: 821–8.
8. Kober L, Torp-Pedersen C, Carlsen JE et al. for the trandolapril cardiac evaluation (TRACE) study group: a clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 33: 1670–6.
9. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system Am Heart J 1994; 127: 1388–401.
10. Ferner RE, Simpson JM, Rawlins MD. Effects of intradermal bradykininn after inhibition of angiotensin converting enzyme. Br Med J 1987; 294: 1119–20.
11. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur Heart J 2004; 25: 1454–70.
12. MacMurray J, Cohen-Solal A, Dietz R et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Failure 2001; 3: 495–502.
2. Pfeffer JM, Pfeffer M, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57: 84–95.
3. Pfeffer MA, Braunwald EA, Moyé LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992; 327: 669–77.
4. De Kam PJ, Voors AA et al. Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilatation after myocardial infarction in patients receiving thrombolysis. J Am Coll Cardiol 2000; 36: 2047–53.
5. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. The prognostic value of predischarge quantitative two-dimensional echocardiographyc measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 trial. Eur Heart J 1996; 17: 1646–56.
6. Greenberg B, Quinones MA et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left netricular dysfunction. Results of the SOLVD Echocardiographic Study. Circulation 1995; 91: 2573–81.
7. Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy. Lancet 1993; 342: 821–8.
8. Kober L, Torp-Pedersen C, Carlsen JE et al. for the trandolapril cardiac evaluation (TRACE) study group: a clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 33: 1670–6.
9. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system Am Heart J 1994; 127: 1388–401.
10. Ferner RE, Simpson JM, Rawlins MD. Effects of intradermal bradykininn after inhibition of angiotensin converting enzyme. Br Med J 1987; 294: 1119–20.
11. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur Heart J 2004; 25: 1454–70.
12. MacMurray J, Cohen-Solal A, Dietz R et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Failure 2001; 3: 495–502.
Авторы
А.С.Галявич
Казанский государственный медицинский университет
Казанский государственный медицинский университет
________________________________________________
A.S. Galyavich
Kazan State Medical University
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.